Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Lytix Biopharma AS banner
L

Lytix Biopharma AS
F:6BG

Watchlist Manager
Lytix Biopharma AS
F:6BG
Watchlist
Price: 0.756 EUR -2.07% Market Closed
Market Cap: €460.1k
Write Note Create Alert Ask AI

Bankruptcy Probability

Lytix Biopharma AS's probability of bankruptcy is 1.2%, making a collapse highly unlikely. The solvency score is 75/100 — a strong indicator of financial stability.

We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.

Very Low
Probability of Bankruptcy

Financial Position

Cash & Short-Term Investments
+
3Y
-5%
5Y
-
10Y
-
Long-Term Investments
+
3Y
-
5Y
-
10Y
-
Debt
+
3Y
-
5Y
-
10Y
-

Solvency Ratios

Solvency Ratios Comparison
Lytix Biopharma AS Competitors

Country Company Market Cap D/E D/A Interest
Coverage 		Altman
Z-Score 		Quick
Ratio 		Current
Ratio 		Cash
Ratio
NO
Lytix Biopharma AS
OSE:LYTIX
643.8m NOK
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
AbbVie Inc
NYSE:ABBV
466.5B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Amgen Inc
NASDAQ:AMGN
205.5B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Gilead Sciences, Inc
NASDAQ:GILD
187.3B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
130.8B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.6B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Moderna Inc
NASDAQ:MRNA
63.1B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
NL
argenx SE
XBRU:ARGX
54.5B EUR
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
AU
CSL Ltd
ASX:CSL
84.1B AUD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Natera Inc
NASDAQ:NTRA
52.6B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Revolution Medicines Inc
NASDAQ:RVMD
42.2B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
No Stocks Found

Continue 6BG Research

Summary
6BG intrinsic value, competitors valuation, and company profile.
DCF Valuation
6BG stock valuation using Discount Cash Flow valuation method.
Relative Valuation
6BG stock valuation using valuation multiples.
Wall St Estimates
6BG price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
6BG stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Lytix Biopharma AS listings:
OSE • NOK
LYTIX
Discover More
Is Lytix Biopharma AS at risk of bankruptcy?

Lytix Biopharma AS's probability of bankruptcy is 1.2%, making a collapse highly unlikely.

The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.

How much debt does Lytix Biopharma AS have?

As of the latest report, Lytix Biopharma AS has total debt of 992k NOK. This includes both short-term (0 NOK) and long-term (992k NOK) debt.

You can find a full breakdown on its Balance Sheet.

Back to Top
ALPHA SPREAD
Follow us
Join 358,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.